According to Fréttablaðið the Icelandic biotech company Kerecis Limited has received a clearance from the Food and Drug Administration (FDA) to market their product, a proprietary fish-skin tissue-regeneration technology for the treatment of chronic wounds, in the United States.
The company was founded in 2009 and develops products that help chronic wounds and damaged tissue to heal. The products are made from cod skin and produced in Iceland. When the product is placed onto damaged tissue, protease activity is modulated, the fish skin is vascularized and populated by the patient's own cells, and ultimately converted into living tissue.
According to Fréttablaðið the Icelandic biotech company Kerecis Limited has received a clearance from the Food and Drug Administration (FDA) to market their product, a proprietary fish-skin tissue-regeneration technology for the treatment of chronic wounds, in the United States.
The company was founded in 2009 and develops products that help chronic wounds and damaged tissue to heal. The products are made from cod skin and produced in Iceland. When the product is placed onto damaged tissue, protease activity is modulated, the fish skin is vascularized and populated by the patient's own cells, and ultimately converted into living tissue.
